At the news
? BEARISHIMPACT 7/10 424B5 filed Apr 13, 2026 at 16:39 ET
Revolution Medicines is conducting a $750 million common stock offering and a concurrent $250 million convertible note offering. The stock offering will dilute existing shareholders and increase capital, while the convertible notes add leverage and potential future dilution upon conversion.
- Revolution Medicines is offering $750 million of common stock
- Concurrently offering $250 million aggregate principal amount of convertible senior notes due 2033
- The two offerings are not contingent on each other's completion
- Stock offering will result in immediate dilution to new investors
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access